BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 37515398)

  • 21. The transmembrane chemokines CXCL16 and CX3CL1 and their receptors are expressed in human meningiomas.
    Li G; Hattermann K; Mentlein R; Mehdorn HM; Held-Feindt J
    Oncol Rep; 2013 Feb; 29(2):563-70. PubMed ID: 23229614
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Differential expression of extracellular matrix-related genes in rare variants of meningioma.
    Kwon MJ; Sung CO; Kang SY; Do IG; Suh YL
    Hum Pathol; 2013 Feb; 44(2):260-8. PubMed ID: 22995327
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Proteomic analysis discovers the differential expression of novel proteins and phosphoproteins in meningioma including NEK9, HK2 and SET and deregulation of RNA metabolism.
    Dunn J; Ferluga S; Sharma V; Futschik M; Hilton DA; Adams CL; Lasonder E; Hanemann CO
    EBioMedicine; 2019 Feb; 40():77-91. PubMed ID: 30594554
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Association between laminin γ1 expression and meningioma grade, recurrence, and progression-free survival.
    Ke HL; Ke RH; Li B; Wang XH; Wang YN; Wang XQ
    Acta Neurochir (Wien); 2013 Jan; 155(1):165-71. PubMed ID: 23053286
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Altered expression of E-Cadherin-related transcription factors indicates partial epithelial-mesenchymal transition in aggressive meningiomas.
    Wallesch M; Pachow D; Blücher C; Firsching R; Warnke JP; Braunsdorf WEK; Kirches E; Mawrin C
    J Neurol Sci; 2017 Sep; 380():112-121. PubMed ID: 28870549
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A role for matrix remodelling proteins in invasive and malignant meningiomas.
    Jalali S; Singh S; Agnihotri S; Wataya T; Salehi F; Alkins R; Burrell K; Navab R; Croul S; Aldape K; Zadeh G
    Neuropathol Appl Neurobiol; 2015 Feb; 41(2):e16-28. PubMed ID: 24989599
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Microarray-based gene expression profiling of benign, atypical and anaplastic meningiomas identifies novel genes associated with meningioma progression.
    Wrobel G; Roerig P; Kokocinski F; Neben K; Hahn M; Reifenberger G; Lichter P
    Int J Cancer; 2005 Mar; 114(2):249-56. PubMed ID: 15540215
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Altered expression of beta-catenin/E-cadherin in meningiomas.
    Brunner EC; Romeike BF; Jung M; Comtesse N; Meese E
    Histopathology; 2006 Aug; 49(2):178-87. PubMed ID: 16879395
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Microarray analysis reveals down-regulation of the tumour suppressor gene WWOX and up-regulation of the oncogene TYMS in intracranial sporadic meningiomas.
    Aarhus M; Bruland O; Bredholt G; Lybaek H; Husebye ES; Krossnes BK; Vedeler C; Wester K; Lund-Johansen M; Knappskog PM
    J Neurooncol; 2008 Jul; 88(3):251-9. PubMed ID: 18365142
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The protein expression profile of meningioma cells is associated with distinct cytogenetic tumour subgroups.
    Domingues PH; Teodósio C; Otero Á; Sousa P; Gonçalves JM; Nieto AB; Lopes MC; de Oliveira C; Orfao A; Tabernero MD
    Neuropathol Appl Neurobiol; 2015 Apr; 41(3):319-32. PubMed ID: 24612434
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Differential expression profiling analyses identifies downregulation of 1p, 6q, and 14q genes and overexpression of 6p histone cluster 1 genes as markers of recurrence in meningiomas.
    Pérez-Magán E; Rodríguez de Lope A; Ribalta T; Ruano Y; Campos-Martín Y; Pérez-Bautista G; García JF; García-Claver A; Fiaño C; Hernández-Moneo JL; Mollejo M; Meléndez B
    Neuro Oncol; 2010 Dec; 12(12):1278-90. PubMed ID: 20685720
    [TBL] [Abstract][Full Text] [Related]  

  • 32. First insight into the somatic mutation burden of neurofibromatosis type 2-associated grade I and grade II meningiomas: a case report comprehensive genomic study of two cranial meningiomas with vastly different clinical presentation.
    Dewan R; Pemov A; Dutra AS; Pak ED; Edwards NA; Ray-Chaudhury A; Hansen NF; Chandrasekharappa SC; Mullikin JC; Asthagiri AR; ; Heiss JD; Stewart DR; Germanwala AV
    BMC Cancer; 2017 Feb; 17(1):127. PubMed ID: 28193203
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Meningioma transcript profiles reveal deregulated Notch signaling pathway.
    Cuevas IC; Slocum AL; Jun P; Costello JF; Bollen AW; Riggins GJ; McDermott MW; Lal A
    Cancer Res; 2005 Jun; 65(12):5070-5. PubMed ID: 15958550
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinicopathological variables, immunophenotype, chromosome 1p36 loss and tumour recurrence of 247 meningiomas grade I and II.
    Ruiz J; Martínez A; Hernández S; Zimman H; Ferrer M; Fernández C; Sáez M; López-Asenjo JA; Sanz-Ortega J
    Histol Histopathol; 2010 Mar; 25(3):341-9. PubMed ID: 20054806
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparative proteomic profiles of meningioma subtypes.
    Okamoto H; Li J; Vortmeyer AO; Jaffe H; Lee YS; Gläsker S; Sohn TS; Zeng W; Ikejiri B; Proescholdt MA; Mayer C; Weil RJ; Oldfield EH; Zhuang Z
    Cancer Res; 2006 Oct; 66(20):10199-204. PubMed ID: 17047085
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Immunocytochemical analysis of glucose transporter protein-1 (GLUT-1) in typical, brain invasive, atypical and anaplastic meningioma.
    van de Nes JA; Griewank KG; Schmid KW; Grabellus F
    Neuropathology; 2015 Feb; 35(1):24-36. PubMed ID: 25168354
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Integrative genomic analysis identifies NDRG2 as a candidate tumor suppressor gene frequently inactivated in clinically aggressive meningioma.
    Lusis EA; Watson MA; Chicoine MR; Lyman M; Roerig P; Reifenberger G; Gutmann DH; Perry A
    Cancer Res; 2005 Aug; 65(16):7121-6. PubMed ID: 16103061
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Histological classification and molecular genetics of meningiomas.
    Riemenschneider MJ; Perry A; Reifenberger G
    Lancet Neurol; 2006 Dec; 5(12):1045-54. PubMed ID: 17110285
    [TBL] [Abstract][Full Text] [Related]  

  • 39. miRNA-145 is downregulated in atypical and anaplastic meningiomas and negatively regulates motility and proliferation of meningioma cells.
    Kliese N; Gobrecht P; Pachow D; Andrae N; Wilisch-Neumann A; Kirches E; Riek-Burchardt M; Angenstein F; Reifenberger G; Riemenschneider MJ; Meese E; Panayotova-Dimitrova D; Gutmann DH; Mawrin C
    Oncogene; 2013 Sep; 32(39):4712-20. PubMed ID: 23108408
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Alterations of INK4a(p16-p14ARF)/INK4b(p15) expression and telomerase activation in meningioma progression.
    Simon M; Park TW; Köster G; Mahlberg R; Hackenbroch M; Boström J; Löning T; Schramm J
    J Neurooncol; 2001 Dec; 55(3):149-58. PubMed ID: 11859969
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.